• 342 Citations
  • 10 h-Index
20082020

Research output per year

If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where Masaya Kai is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 11 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output

  • 342 Citations
  • 10 h-Index
  • 21 Article

Microsatellite instability in Japanese female patients with triple-negative breast cancer

Kurata, K., Kubo, M., Kai, M., Mori, H., Kawaji, H., Kaneshiro, K., Yamada, M., Nishimura, R., Osako, T., Arima, N., Okido, M., Oda, Y. & Nakamura, M., May 1 2020, In : Breast Cancer. 27, 3, p. 490-498 9 p.

Research output: Contribution to journalArticle

Open Access
  • 1 Citation (Scopus)

    T-bet+ lymphocytes infiltration as an independent better prognostic indicator for triple-negative breast cancer

    Mori, H., Kubo, M., Kai, M., Yamada, M., Kurata, K., Kawaji, H., Kaneshiro, K., Osako, T., Nishimura, R., Arima, N., Okido, M., Kishimoto, J., Oda, Y. & Nakamura, M., Aug 15 2019, In : Breast Cancer Research and Treatment. 176, 3, p. 569-577 9 p.

    Research output: Contribution to journalArticle

    Open Access
  • 3 Citations (Scopus)

    BRCAness Combined With a Family History of Cancer Is Associated With a Poor Prognosis for Breast Cancer Patients With a High Risk of BRCA Mutations

    Mori, H., Kubo, M., Kai, M., Velasquez, V. V., Kurata, K., Yamada, M., Okido, M., Kuroki, S., Oda, Y. & Nakamura, M., Oct 2018, In : Clinical Breast Cancer. 18, 5, p. e1217-e1227

    Research output: Contribution to journalArticle

  • 1 Citation (Scopus)

    Catumaxomab with activated T-cells efficiently lyses chemoresistant EpCAM-positive triple-negative breast cancer cell lines

    Kubo, M., Umebayashi, M., Kurata, K., Mori, H., Kai, M., Onishi, H., Katano, M., Nakamura, M. & Morisaki, T., Jul 2018, In : Anticancer research. 38, 7, p. 4273-4279 7 p.

    Research output: Contribution to journalArticle

  • 1 Citation (Scopus)

    Dual mTOR kinase inhibitor MLN0128 sensitize HR þ /HER2 þ breast cancer patient-Derived xenografts to trastuzumab or fulvestrant

    Hsu, P. Y., Wu, V. S., Kanaya, N., Petrossian, K., Hsu, H. K., Nguyen, D., Schmolze, D., Kai, M., Liu, C. Y., Lu, H., Chu, P., Vito, C. A., Kruper, L., Mortimer, J. & Chen, S., Jan 15 2018, In : Clinical Cancer Research. 24, 2, p. 395-406 12 p.

    Research output: Contribution to journalArticle

  • 5 Citations (Scopus)